

---

**SUBJECT:** RSV Immunization Programs – Fall/Winter 2025/26  
**Date:** September 17, 2025  
**Pages:** 2  
**To:** Primary Care Providers, Hospitals, Long-Term Care Homes, Retirement Homes  
**From:** Dr. Matthew Tenenbaum, Associate Medical Officer of Health

---

- Arexvy, Abrysvo, and Beyfortus will be available to order from WDGPB this fall.
- All adults 75 years of age and older will now be eligible for Arexvy/Abrysvo.
- Offer Beyfortus to infants (born after Apr 1, <8 months old) and high-risk children.

Provincial publicly funded RSV programs will continue in Fall/Winter 2025/26. Please see below for updates and other key information.

## Older Adult RSV Program

The vaccines **Arexvy** and/or **Abrysvo** will be available to the following groups:

- All adults **75 years of age and older** (**NEW** for 2025/26)
- Adults **60 years of age and older** who are:
  - Residing in a long-term care home, retirement home, or elder care lodge
  - Receiving alternate level of care (ALC) in hospital
  - Patients with glomerulonephritis (GN) who are moderately to severely immunocompromised (**NEW** for 2025/26)
  - Receiving hemodialysis or peritoneal dialysis
  - Recipients of solid organ or hematopoietic stem cell transplants
  - Experiencing homelessness
  - Individuals who identify as First Nations, Inuit, or Métis

Individuals who previously received an RSV vaccine do not need to be re-immunized.

For additional information, please refer to the [Ministry's Older Adult High-Risk Respiratory Syncytial Virus \(RSV\) Vaccine Program Fact Sheet](#).

## Infant & High-Risk Child RSV Program

The monoclonal antibody product **Beyfortus (nirsevimab)** will be available for the following eligible groups:

- Infants born on or after April 1 and <8 months old at the time of administration
- Children **up to 24 months old** with any risk factor:
  - Chronic lung disease of prematurity, including bronchopulmonary dysplasia<sup>1</sup>
  - Hemodynamically significant congenital heart disease
  - Severe immunodeficiency
  - Down Syndrome / Trisomy 21
  - Cystic fibrosis with recurrent pulmonary exacerbations, pulmonary deterioration, and/or severe growth delay

**WDG Public Health Physicians Advisory**  
**RSV Immunization Programs – Fall/Winter 2025/26**  
**September 17, 2025**  
Page 2 of 2

- Neuromuscular disease or severe congenital airway anomalies impairing clearing of respiratory secretion

1. Children who were <12 months old in the 2024/25 season and eligible under this criterion remain eligible, regardless of their current clinical status.

Dosing remains age and weight-based:

| Infants (1 <sup>st</sup> RSV Season) |               | Children (2 <sup>nd</sup> RSV Season) |
|--------------------------------------|---------------|---------------------------------------|
| < 5 kg                               | ≥ 5 kg        |                                       |
| 50 mg (0.5 mL)                       | 100 mg (1 mL) | 200 mg (2 x 1 mL)                     |

Children who received Beyfortus last season should receive it again this season, if they are still eligible. Each dose only provides protection for a single RSV season.

The vaccine **Abrysvo** will be available for **pregnant individuals between 32-36 weeks GA** who will deliver during the RSV season (November through March).

Beyfortus is still recommended over Abrysvo as a means of protecting infants from RSV. Administration of both is not recommended unless:

- Infant was born <14 days after Abrysvo was administered
- Infant is premature (<37 weeks GA)
- Infant has any risk factor listed above

*For additional information, please refer to the [Ministry's Infant and High-risk Children Respiratory Syncytial Virus \(RSV\) Prevention Program Fact Sheet](#).*

## Ordering

Arexvy and Abrysvo will be available to order mid-September.  
Beyfortus will be available to order on October 1, 2025.

WDGPH will work directly with long-term care homes and retirement homes to coordinate vaccine distribution. Community-based health care providers should use the attached WDG Public Health RSV order form and fax to 519-823-4903.

Arexvy, Abrysvo, and Beyfortus can all be co-administered with flu, COVID, and other routine vaccines.

## For more information, please contact:

Karen Mulvey, Manager, Vaccine Preventable Diseases  
Karen.Mulvey@wdgpublichealth.ca  
[www.wdgpublichealth.ca](http://www.wdgpublichealth.ca)